234 related articles for article (PubMed ID: 14965203)
1. Statin treatment and the natural history of atherosclerotic-related diseases: pathogenic mechanisms and the risk-benefit profile.
Napoli C; Sica V
Curr Pharm Des; 2004; 10(4):425-32. PubMed ID: 14965203
[TBL] [Abstract][Full Text] [Related]
2. A safety look at currently available statins.
Moghadasian MH
Expert Opin Drug Saf; 2002 Sep; 1(3):269-74. PubMed ID: 12904142
[TBL] [Abstract][Full Text] [Related]
3. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
Cziraky MJ; Watson KE; Talbert RL
J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
[TBL] [Abstract][Full Text] [Related]
4. Optimal management of combined dyslipidemia: what have we behind statins monotherapy?
Tenenbaum A; Fisman EZ; Motro M; Adler Y
Adv Cardiol; 2008; 45():127-153. PubMed ID: 18230960
[TBL] [Abstract][Full Text] [Related]
5. Anti-atherosclerotic effects of statins: lessons from prevention trials.
Ganesh SK; Nass CM; Blumenthal RS
J Cardiovasc Risk; 2003 Jun; 10(3):155-9. PubMed ID: 12775947
[TBL] [Abstract][Full Text] [Related]
6. Pleiotropic effects of statins: evidence against benefits beyond LDL-cholesterol lowering.
Pedersen TR
Am J Cardiovasc Drugs; 2010; 10 Suppl 1():10-7. PubMed ID: 21391729
[TBL] [Abstract][Full Text] [Related]
7. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.
Sahebkar A; Watts GF
Clin Ther; 2013 Aug; 35(8):1082-98. PubMed ID: 23932550
[TBL] [Abstract][Full Text] [Related]
8. Are all statins the same? Focus on the efficacy and tolerability of pitavastatin.
da Silva PM
Am J Cardiovasc Drugs; 2011; 11(2):93-107. PubMed ID: 21446776
[TBL] [Abstract][Full Text] [Related]
9. Statin pleiotropy: fact or fiction?
Futterman LG; Lemberg L
Am J Crit Care; 2004 May; 13(3):244-9. PubMed ID: 15149060
[TBL] [Abstract][Full Text] [Related]
10. Effects of HMG-CoA reductase inhibitors on skeletal muscle: are all statins the same?
Evans M; Rees A
Drug Saf; 2002; 25(9):649-63. PubMed ID: 12137559
[TBL] [Abstract][Full Text] [Related]
11. Pitavastatin: novel effects on lipid parameters.
Chapman MJ
Atheroscler Suppl; 2011 Nov; 12(3):277-84. PubMed ID: 22152282
[TBL] [Abstract][Full Text] [Related]
12. Statins: potent vascular anti-inflammatory agents.
Liao JK
Int J Clin Pract Suppl; 2004 Oct; (143):41-8. PubMed ID: 16035395
[TBL] [Abstract][Full Text] [Related]
13. Rosuvastatin-associated adverse effects and drug-drug interactions in the clinical setting of dyslipidemia.
Kostapanos MS; Milionis HJ; Elisaf MS
Am J Cardiovasc Drugs; 2010; 10(1):11-28. PubMed ID: 20104931
[TBL] [Abstract][Full Text] [Related]
14. Hypertriglyceridemia: a review of clinical relevance and treatment options: focus on cerivastatin.
Breuer HW
Curr Med Res Opin; 2001; 17(1):60-73. PubMed ID: 11464448
[TBL] [Abstract][Full Text] [Related]
15. Medical lipid-regulating therapy: current evidence, ongoing trials and future developments.
Evans M; Roberts A; Davies S; Rees A
Drugs; 2004; 64(11):1181-96. PubMed ID: 15161326
[TBL] [Abstract][Full Text] [Related]
16. The evolving role of statins in the management of atherosclerosis.
Vaughan CJ; Gotto AM; Basson CT
J Am Coll Cardiol; 2000 Jan; 35(1):1-10. PubMed ID: 10636252
[TBL] [Abstract][Full Text] [Related]
17. Beyond lipid-lowering: effects of statins on endothelial nitric oxide.
Laufs U
Eur J Clin Pharmacol; 2003 Mar; 58(11):719-31. PubMed ID: 12634978
[TBL] [Abstract][Full Text] [Related]
18. Statins and coronary artery disease: clinical evidence and future perspective.
Biasucci LM; Stefanelli A; Biasillo G
Minerva Cardioangiol; 2012 Apr; 60(2):147-56. PubMed ID: 22495163
[TBL] [Abstract][Full Text] [Related]
19. [Statins have other beneficial properties besides their cholesterol lowering effect].
Eriksson M
Lakartidningen; 1998 Aug; 95(35):3670-2. PubMed ID: 9748780
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
